<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529243</url>
  </required_header>
  <id_info>
    <org_study_id>4908</org_study_id>
    <nct_id>NCT00529243</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects</brief_title>
  <acronym>CHEER</acronym>
  <official_title>Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is:

      To assess the virologic effect of changing enfuvirtide to MK-0518(raltegravir) in human
      immunodeficiency virus type 1(HIV-1) infected patients who have an undetectable level of
      serum human immunodeficiency virus(HIV) (&lt; 75 copies/ml by branch deoxyribonucleic acid
      (bDNA) assay, &lt; 50 copies/ml by Ultrasensitive Polymerase Chain Reaction(PCR) assay) on their
      current HIV medication regimen.

      Hypothesis:

      HIV-1 infected individuals well controlled on an enfuvirtide containing regimen with HIV RNA
      levels below limits of quantification can safely have the investigational integrase
      inhibitor, MK-0518 substituted for enfuvirtide without loss of virologic suppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human immunodeficiency virus type 1(HIV-1) infected patients who have had an undetectable
      viral load on an enfuvirtide containing regimen at the Kaiser Permanente Hayward, Los
      Angeles, San Francisco, and Santa Clara Medical Centers will be enrolled. Patients will
      receive open label MK-0518 (raltegravir) 400mg orally twice a day as substitution for
      enfuvirtide for 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Undetectable Human Immunodeficiency Virus (HIV) Viral Load at Week 24.</measure>
    <time_frame>24 Weeks</time_frame>
    <description>To assess the virologic effect of changing enfuvirtide to MK-0518 (raltegravir) in human immunodeficiency virus type 1 (HIV-1) infected patients who have an undetectable level of serum HIV (undetectable level of serum HIV defined as &lt; 75 copies/ml by bDNA assay or &lt; 50 copies/ml by Ultrasensitive PCR assay) on their current HIV medication regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Change in Cluster of Differentiation 4(CD4) Cell Count From Baseline at Week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <description>To study the immunologic effect of changing enfuvirtide to MK-0518 (raltegravir) in HIV-1 infected patients who have an undetectable level of serum HIV (undetectable serum HIV defined as &lt; 75 copies/ml by bDNA assay or &lt; 50 copies/ml by Ultrasensitive PCR assay)on their current HIV medication regimen.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>MK-0518 (raltegravir)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.</description>
    <arm_group_label>MK-0518 (raltegravir)</arm_group_label>
    <other_name>MK-0518, Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must meet all of the following inclusion criteria to be eligible for
             participation in this study.

               1. Subject is ≥ 18 years of age and able to understand and willing to sign a written
                  informed consent form, which must be obtained prior to initiation of the study.

               2. Documented laboratory diagnosis of HIV-1 infection (positive Enzyme-linked
                  immunosorbent assay (ELISA) HIV-1 antibody test confirmed by western blot, p24
                  assay, HIV-1 RNA, or culture).

               3. Have documented plasma HIV-1 RNA level(s) of &lt; 75 copies/ml by branched
                  deoxyribonucleic acid(bDNA) assay, or &lt; 50 copies/ml by Ultrasensitive Polymerase
                  Chain Reaction(PCR) for at least 6 months prior to screening visit.

               4. Currently receiving a stable antiretroviral regimen consisting of enfuvirtide
                  plus at least 2 other antiretrovirals for at least 6 months.

               5. Negative serum pregnancy test (females of childbearing potential only) and are
                  willing to use an adequate method of contraception throughout the duration of the
                  study.

        Exclusion Criteria:

          -  Patients who meet any of the following exclusion criteria are not to be enrolled in
             this study.

               1. Any prior therapy with MK-0518 or any other HIV-1 integrase inhibitor.

               2. Any HIV-1 viral load &gt; 75 copies/ml by bDNA assay, or &gt; 50 copies/ml by
                  Ultrasensitive PCR assay in the 6 months prior to screening visit (A single
                  &quot;blip&quot; of HIV-1 viral load &gt;75 copies but &lt;400 copies by bDNA assay, or &gt;50
                  copies but &lt;400 copies by Ultrasensitive PCR assay in the six months prior to
                  screening visit with at least one subsequent HIV-1 viral load below the limit of
                  detection will be accepted.)

               3. Any previous known hypersensitivity to components of the study drug formulation.

               4. Weight &lt; 40 kilograms.

               5. Patient requires or is anticipated to require any of the prohibited medications
                  noted in the protocol.

               6. Acute therapy for serious illness (in the opinion of the investigator) within 14
                  days prior to study entry unless the subject has completed ≥ 7 days of therapy
                  and is considered clinically stable by the investigator.

               7. Any condition which, in the opinion of the investigator, would compromise the
                  subject's ability to participate in the study.

               8. Any active opportunistic infections or Centers for Disease Control and Prevention
                  (CDC) Category C conditions (with the exception of stable cutaneous Kaposi's
                  Sarcoma and wasting syndrome due to HIV infection).

               9. Any malignancy requiring chemotherapy.

              10. Subject has any of the following laboratory results at screening:

                  Hemoglobin &lt; 8.0 gr/dl Absolute neutrophil count &lt; 750 cells/ml Platelet count &lt;
                  40,000 Creatinine &gt; 2.0 or calculated creatinine clearance &lt; 40 ml/min

              11. Female patient who is pregnant or breast-feeding, or expecting to conceive or
                  donate eggs during the study. Male patient who is planning to impregnate or
                  provide sperm donation during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J Towner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Anaheim</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Hayward</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>95454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser West Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Panorama City</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Santa Clarita</name>
      <address>
        <city>Santa Clarita</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>May 9, 2011</results_first_submitted>
  <results_first_submitted_qc>May 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2011</results_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experience</keyword>
  <keyword>On enfuvirtide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Enfuvirtide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A multicenter study that enrolled patients from 11 Kaiser Permanente Human Immunodeficiency Virus (HIV) clinics in California. 54 patients were screened. Two patients did not meet protocol inclusion criteria.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MK-0518 (Raltegravir)</title>
          <description>Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-0518 (Raltegravir)</title>
          <description>Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="40" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time of Prior Antiretroviral Therapy Use</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="7" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Past Antiretrovials Used</title>
          <units>medications</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="4" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time on Enfuvirtide Therapy</title>
          <description>mean length of time on enfuvirtide therapy before change to MK-0518 (raltegravir)</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="997" lower_limit="264" upper_limit="2457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Undetectable Human Immunodeficiency Virus (HIV) Viral Load at Week 24.</title>
        <description>To assess the virologic effect of changing enfuvirtide to MK-0518 (raltegravir) in human immunodeficiency virus type 1 (HIV-1) infected patients who have an undetectable level of serum HIV (undetectable level of serum HIV defined as &lt; 75 copies/ml by bDNA assay or &lt; 50 copies/ml by Ultrasensitive PCR assay) on their current HIV medication regimen.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Analysis used the intent to treat (ITT) population, defined as all patients who received at least one dose of raltegravir.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0518 (Raltegravir)</title>
            <description>Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Undetectable Human Immunodeficiency Virus (HIV) Viral Load at Week 24.</title>
          <description>To assess the virologic effect of changing enfuvirtide to MK-0518 (raltegravir) in human immunodeficiency virus type 1 (HIV-1) infected patients who have an undetectable level of serum HIV (undetectable level of serum HIV defined as &lt; 75 copies/ml by bDNA assay or &lt; 50 copies/ml by Ultrasensitive PCR assay) on their current HIV medication regimen.</description>
          <population>Analysis used the intent to treat (ITT) population, defined as all patients who received at least one dose of raltegravir.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change in Cluster of Differentiation 4(CD4) Cell Count From Baseline at Week 24</title>
        <description>To study the immunologic effect of changing enfuvirtide to MK-0518 (raltegravir) in HIV-1 infected patients who have an undetectable level of serum HIV (undetectable serum HIV defined as &lt; 75 copies/ml by bDNA assay or &lt; 50 copies/ml by Ultrasensitive PCR assay)on their current HIV medication regimen.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Analysis was per intention to treat (ITT) population defined as all patients who received at least one dose of raltegravir.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0518 (Raltegravir)</title>
            <description>Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change in Cluster of Differentiation 4(CD4) Cell Count From Baseline at Week 24</title>
          <description>To study the immunologic effect of changing enfuvirtide to MK-0518 (raltegravir) in HIV-1 infected patients who have an undetectable level of serum HIV (undetectable serum HIV defined as &lt; 75 copies/ml by bDNA assay or &lt; 50 copies/ml by Ultrasensitive PCR assay)on their current HIV medication regimen.</description>
          <population>Analysis was per intention to treat (ITT) population defined as all patients who received at least one dose of raltegravir.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="-165" upper_limit="1362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>33 Weeks</time_frame>
      <desc>Any adverse event (i.e., a new event or an exacerbation of a pre-existing condition) with an onset date after study drug administration up to the last day on study (including the follow-up, off study medication period of the study), should be recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-0518 (Raltegravir)</title>
          <description>Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Septicemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Patient with history of gastroparesis &amp; delayed emptying unrelated to his HIV disease died 12 weeks into the study, assessed due to worsening of malnourishment and dehydration not due to his antiretroviral medications or study participation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase (ALT)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>serum creatinine elevation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation of our study was the lack of a separate control arm. However, patients did serve as their own control by virtue of at least 6 months of HIV-1 ribonucleic acid(RNA)levels below the level of quantification before enrollment in the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William Towner, MD</name_or_title>
      <organization>Kaiser Permanente</organization>
      <phone>323-783-7855</phone>
      <email>William.J.Towner@KP.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

